Erin E Franklin1, Richard J Perrin2, Benjamin Vincent2, Michael Baxter2, John C Morris3, Nigel J Cairns3. 1. Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: efranklin@path.wustl.edu. 2. Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. 3. Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Abstract
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core (ADNI-NPC) facilitates brain donation, ensures standardized neuropathologic assessments, and maintains a tissue resource for research. METHODS: The ADNI-NPC coordinates with performance sites to promote autopsy consent, facilitate tissue collection and autopsy administration, and arrange sample delivery to the NPC, for assessment using National Institute on Aging-Alzheimer's Association neuropathologic diagnostic criteria. RESULTS: The ADNI-NPC has obtained 45 participant specimens, and neuropathologic assessments have been completed in 36 to date. Challenges in obtaining consent at some sites have limited the voluntary autopsy rate to 58%. Among assessed cases, clinical diagnostic accuracy for Alzheimer disease (AD) is 97%; however, 58% of cases show neuropathologic comorbidities. DISCUSSION: Challenges facing autopsy consent and coordination are largely resource related. The neuropathologic assessments indicate that ADNI's clinical diagnostic accuracy for AD is high; however, many AD cases have comorbidities that may impact the clinical presentation, course, and imaging and biomarker results. These neuropathologic data permit multimodal and genetic studies of these comorbidities to improve diagnosis and provide etiologic insights.
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core (ADNI-NPC) facilitates brain donation, ensures standardized neuropathologic assessments, and maintains a tissue resource for research. METHODS: The ADNI-NPC coordinates with performance sites to promote autopsy consent, facilitate tissue collection and autopsy administration, and arrange sample delivery to the NPC, for assessment using National Institute on Aging-Alzheimer's Association neuropathologic diagnostic criteria. RESULTS: The ADNI-NPC has obtained 45 participant specimens, and neuropathologic assessments have been completed in 36 to date. Challenges in obtaining consent at some sites have limited the voluntary autopsy rate to 58%. Among assessed cases, clinical diagnostic accuracy for Alzheimer disease (AD) is 97%; however, 58% of cases show neuropathologic comorbidities. DISCUSSION: Challenges facing autopsy consent and coordination are largely resource related. The neuropathologic assessments indicate that ADNI's clinical diagnostic accuracy for AD is high; however, many AD cases have comorbidities that may impact the clinical presentation, course, and imaging and biomarker results. These neuropathologic data permit multimodal and genetic studies of these comorbidities to improve diagnosis and provide etiologic insights.
Authors: Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman Journal: Acta Neuropathol Date: 2011-11-20 Impact factor: 17.088
Authors: Manuela Neumann; Sigrun Roeber; Hans A Kretzschmar; Rosa Rademakers; Matt Baker; Ian R A Mackenzie Journal: Acta Neuropathol Date: 2009-08-09 Impact factor: 17.088
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris Journal: Arch Neurol Date: 2009-12
Authors: Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2008-11-18 Impact factor: 17.088
Authors: Manuela Neumann; Rosa Rademakers; Sigrun Roeber; Matt Baker; Hans A Kretzschmar; Ian R A Mackenzie Journal: Brain Date: 2009-08-11 Impact factor: 13.501
Authors: I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada Journal: Neurology Date: 2005-10-19 Impact factor: 9.910
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Sandra Espinoza; Felipe Grunenwald; Wileidy Gomez; Felipe García; Lorena Abarzúa-Catalan; Sebastián Oyarce-Pezoa; Maria Fernanda Hernandez; Bastián I Cortés; Markus Uhrig; Daniela P Ponce; Claudia Durán-Aniotz; Claudio Hetz; Carol D SanMartín; Victor H Cornejo; Fernando Ezquer; Valentina Parra; Maria Isabel Behrens; Patricio A Manque; Diego Rojas-Rivera; René L Vidal; Ute Woehlbier; Melissa Nassif Journal: Cells Date: 2022-06-07 Impact factor: 7.666
Authors: Lincoln Mp Shade; Yuriko Katsumata; Timothy J Hohman; Kwangsik Nho; Andrew J Saykin; Shubhabrata Mukherjee; Kevin L Boehme; John Sk Kauwe; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Richard P Mayeux; Julie A Schneider; Peter T Nelson; David W Fardo Journal: J Cereb Blood Flow Metab Date: 2022-02-14 Impact factor: 6.960
Authors: W R Wayne Martin; Michael Miles; Qiaonan Zhong; Johanna Hartlein; Brad A Racette; Scott A Norris; Mwiza Ushe; Baijayanta Maiti; Susan Criswell; Albert A Davis; Paul T Kotzbauer; Nigel J Cairns; Richard J Perrin; Joel S Perlmutter Journal: Mov Disord Date: 2020-11-30 Impact factor: 10.338
Authors: Erik Portelius; Bob Olsson; Kina Höglund; Nicholas C Cullen; Hlin Kvartsberg; Ulf Andreasson; Henrik Zetterberg; Åsa Sandelius; Leslie M Shaw; Virginia M Y Lee; David J Irwin; Murray Grossman; Daniel Weintraub; Alice Chen-Plotkin; David A Wolk; Leo McCluskey; Lauren Elman; Jennifer McBride; Jon B Toledo; John Q Trojanowski; Kaj Blennow Journal: Acta Neuropathol Date: 2018-04-26 Impact factor: 17.088
Authors: Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz Journal: Neurology Date: 2017-10-25 Impact factor: 9.910